(A/Anhui/1/2013) NA / Neuraminidase Protein Product Information
A DNA sequence
Influenza A virus
> 95 % as determined by SDS-PAGE
H7N9 NA protein
Measured by its ability to cleave a fluorogenic
< 1.0 EU per μg of the protein as determined by the
Samples are stable for up to twelve months from date of
Predicted N terminal:
Lyophilized from sterile PBS, pH 7.4.
HHHHHHHHHH LEVLFQGPHL KPGCNCSHSQ PETTNTSQTI INNYYNETNI
Store it under sterile conditions at -70℃ . It is recommended that
A hardcopy of COA with reconstitution instruction is
H7N9 is a subtype of
Influenza virus A. On April 1, 2013, the World Health Organization (WHO) first
reported 3 human infections with a new influenza A (H7N9) virus in China . Since
then, additional cases have been reported. This new H7N9 virus is an avian
(bird) influenza (flu) virus. Influenza (flu) is a respiratory infection in
mammals and birds. The virus is divided into three main types (Influenza A,
Influenza B, and Influenza C), which are distinguished by differences in two
major internal proteins (hemagglutinin (HA) and neuraminidase (NA)). The
influenza viral neuraminidase (NA) protein is a tetramer with an enzyme active
site on the head of each monomer. Subtypes are further divided into strains;
each genetically distinct virus isolate is usually considered to be a separate
strain. NA protein is a second major surface antigen of the virion.
Neuraminidase (NA) cleaves terminal sialic acid from glycoproteins or
glycolipids. Thus, it functions to free virus particles from host cell
receptors, to permit progeny virions to escape from the cell in which they
arose, and so facilitate virus spread.
Suzuki T. et al., 2005, J Virol. 79: 11705-15.
Shinya K. et al., 2006, Nature. 440 (7083): 435-6.
Von Itzstein M. 2007, Nat Rev Drug Discov. 6: 967-74.
Christophe F. et al., 2009, Science. 324: 1557-61.
Marjuki H. et al., 2006, J Biol Chem. 281: 16707-15.
Christophe F. et al., 2009, Science. 324:1557-61.